Roche Holding Ltd. (ADR)

  • Understanding The Massive Market Potential of Monoclonal Antibodies

    By Leo Sun - August 19, 2013 | Tickers: ABBV, LLY, JNJ, RHHBY

    Over the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules which mimic naturally produced antibodies, forming the foundation of cutting edge oncology treatments, such as antibody drug conjugates (ADCs), biologics, and immunotherapy, which all aim to reduce or eliminate the use of traditional chemotherapy.

    Monoclonal antibodies, which are administered intravenously, have a wide variety of applications, including cancer cell marking, growth signal blocking, the more »

  • Which Of These Smaller Companies Could Roche Buy?

    By Leo Sun - August 16, 2013 | Tickers: ALXN, CLDX, IMUC, IMMU, RHHBY

    Over this past year, the oncology treatment industry has been a hotbed of acquisition rumors, which caused analysts and investors to endlessly speculate on which companies will be swallowed up next by the larger fish in the sea. In a previous article, I visited the eye of the storm: Onyx Pharmaceuticals, which put itself on sale after a failed $8.7 billion buyout attempt from Amgen. Amgen is reportedly still more »

  • A Pharmacology Primer for the Biotech Investor

    By Seth Robey - August 16, 2013 | Tickers: LLY, MNKD, NVO, RHHBY

    In Pharmacology we don't only have to consider the actions of the drug on the body.  It is also important to understand the way the body processes the drug, or the Pharmacokinetics.  When you consider that drugs, like the nutrients in food, must be absorbed (A), distributed (D) throughout the body, metabolized (M), and excreted/eliminated (E), pharmacokinetics becomes a critical consideration in drug development.  Investors with a keen more »

  • Is This New Lung Cancer Treatment a Game Changer?

    By Leo Sun - August 16, 2013 | Tickers: LLY, PFE, RHHBY

    Eli Lilly (NYSE: LLY) rallied on Aug. 13 after the pharmaceutical giant announced that its Phase III trial for a lung cancer treatment had succeeded in increasing the overall survival rate of patients. Analysts immediately speculated that this new treatment could become a blockbuster drug, possibly softening the blow from the upcoming patent expiration of Lilly’s best-selling product, Cymbalta.

    Is this unexpected victory reason to pick up shares of more »

  • Which of These Biotechs Can Beat the Bird Flu?

    By Leo Sun - August 15, 2013 | Tickers: BOTA, GILD, GSK, RHHBY, SNY

    The H7N9 bird flu epidemic, which recently claimed its 44th victim in China, has had a widespread impact across the markets, ravaging the airline, hospitality and restaurant sectors in particular. Since the end of March, the Chinese government reported 134 new cases of N7N9, with a single overseas case reported in Taiwan.

    H7N9 is more lethal than its predecessor, H5N1, which claimed more than 360 lives over the past decade more »

  • Is This Biotech Slowing?

    By Brandy Betz - August 9, 2013 | Tickers: REGN, RHHBY, SNY

    Regeneron Pharmaceuticals (NASDAQ: REGN) closed Tuesday down over 6% following a second quarter report that missed estimates. A particular cause for concern was the slowed sales growth for macular degeneration drug Eylea. Were investors right to run away?

    If you Google Regeneron’s second quarter right now, you’ll see an odd mix of headlines touting either Eylea’s slowdown or its sales jump. So which is it? It’s more »

  • Should You Keep an Eye on These Eye Treatment Biotechs?

    By Leo Sun - August 8, 2013 | Tickers: AMPE, NVS, REGN, RHHBY

    Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector. Two eye diseases -- wet AMD (age-related macular degeneration) and DME (diabetic macular edema) -- are at the center of a big battle that includes Roche (NASDAQOTH: RHHBY), Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Ampio Pharmaceuticals (NYSEMKT: AMPE).

    Wet (neovascular) AMD causes abnormal blood vessels to more »

  • This Orphan Drug Company Only Appears Expensive

    By Kanak Kanti - August 5, 2013 | Tickers: ALXN, ONXX, RHHBY

    In the last couple of months, we saw two big offers being made - and rejected - in the biotech sector. Both times, the companies that rejected these offers saw huge spikes in their respective stocks. Alexion (NASDAQ: ALXN) rejected an informal takeover proposal from Roche (NASDAQOTH: RHHBY) and went up 7%. Earlier, Onyx (NASDAQ: ONXX) rejected Amgen’s takeover bid and went up 50%.

    Investors generally need not worry that these more »

  • Who Stands to Lose the Most From This Biotech Breakup?

    By Leo Sun - August 2, 2013 | Tickers: BAX, HALO, PFE, RHHBY, VPHM

    Shares of ViroPharma (NASDAQ: VPHM) and Halozyme Therapeutics (NASDAQ: HALO) dropped in tandem on August 1, after ViroPharma discontinued a Phase II study of administering its flagship drug, Cinryze, subcutaneously with Halozyme’s recombinant human enzyme technology. ViroPharma shares declined nearly 7% after the announcement, but Halozyme plunged almost 14%, due to ViroPharma’s statement that it would pursue similar studies for subcutaneous injection by using other products, which raised more »

  • Extremely Expensive Drugs for Extremely Rare Diseases

    By Leo Sun - July 26, 2013 | Tickers: ALXN, NVS, PDLI, RHHBY

    The biotech industry is known for fast paced acquisitions and rapid market consolidation. Larger pharmaceutical companies headed towards patent cliffs often scramble to acquire smaller companies to revive their drying pipelines. Meanwhile, startups frequently go public without any market approved drugs or sources of revenue. Sometimes, large fish get swallowed by even larger ones, and these acquisitions can secure important sources of constant revenue growth for years to come.

    One more »

  • Is This Delivery-Focused Biotech a Buy?

    By Sherrie Stone - July 22, 2013 | Tickers: BAX, HALO, RHHBY

    Editor’s Note: A previous version of this article referred to rHuPH20 as Hylenex.

    Halozyme Therapeutics (NASDAQ: HALO) moved higher by 25% on Friday behind the news of a positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Roche’s Herceptin SC for European approval. This almost certainly signals an EU approval for Herceptin SC, and this is tremendous news for Halozyme more »

  • The Upside in a Revolutionary Treatment For Brain Cancers

    By Kanak Kanti - July 22, 2013 | Tickers: CLDX, MRK, RHHBY

    Every year, 13,000 Americans die due to brain tumors, with glioblastoma multiforme (GBM), the most common form of brain cancer, being responsible for more than 50% of fatalities. GBM has an incidence rate of 12,000 new cases per year in the US alone. Conventional therapies like surgery, radiation and chemotherapy do not work well in the sensitive brain area and have too much collateral damage. Now, a novel more »

  • 4 Reasons This Biotech Went up by 400 Percent

    By Kanak Kanti - July 16, 2013 | Tickers: ALXN, CLDX, RHHBY

    Celldex (NASDAQ: CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some time now. Obviously analysts were bang on target as the stock has gone up more than 51% in a matter of five days and gained an astounding 400% in 52 weeks. The stock is currently trading at around $20 a pop, up from about $4 a year ago.What is moving more »

  • How to Spot the Next Ten Bagger

    By Shmulik Karpf - July 16, 2013 | Tickers: A, BDX, RHHBY

    In his classic book, "Common Stocks And Uncommon Profits," Philip Fisher describes the attributes of a great investment, one that will return hundreds of percent in gains to its investors.

    One of his main principles to look for in a winning stock is how much the prospective company spends on research and development (R&D). He explains that the only way an investor can realistically expect consistent gains over ten more »

  • Is Big Pharma Crazy for Chasing This Deal?

    By Sherrie Stone - July 15, 2013 | Tickers: ALXN, RHHBY

    According to a Bloomberg report, Roche (NASDAQOTH: RHHBY) is prepared to offer $130 a share to purchase Alexion Pharmaceuticals (NASDAQ: ALXN). In other words, Roche is attempting to pay 20 times Alexion’s annual sales, which would give Roche just one FDA-approved product. Is this company crazy?

    What Is So Attractive?

    Alexion’s Soliris is FDA-approved for two indications: Paroxysmal Nocturnal Hemogloinuria (PNH) and Atyptical Hemolytic Uremic Syndrome (aHUS). Both more »

  • Is This Rally Close to Over?

    By Sherrie Stone - July 9, 2013 | Tickers: CLDX, MRK, RHHBY

    I, for one, have been on the Celldex Therapeutics (NASDAQ: CLDX) bandwagon since December 2012. It was at this time that the outlook for Celldex changed from being a speculative biotechnology company to a real player in the cancer immunotherapy space with the clinical success of its breast cancer drug CDX-011.

    CDX-011 has created a lot of excitement, and rightfully so. It is successfully treating patients who have failed multiple more »

  • Is This Eye Drug Worth The Hype?

    By Sherrie Stone - June 21, 2013 | Tickers: AMPE, REGN, RHHBY

    Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions and Roche's vaccine market share. This has been corrected and Motley Fool sincerely apologizes for the error.

    Regeneron Pharmaceuticals (NASDAQ: REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea.

    Regeneron Pharmaceuticals is a $25 more »

  • Can Avastin’s Shortcomings Open the Door for Del Mar Pharmaceuticals?

    By Craig Keolanui - June 14, 2013 | Tickers: MRK, PPHM, RHHBY, TEVA

    The effectiveness of Genentech and Roche's (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin's approval for treating GBM. GBM is one of the hardest indications of cancer to treat with a median survival of about 4.5 months without treatment and less more »

  • Why ImmunoGen Is a Buy Right Now?

    By Kanak Kanti - June 14, 2013 | Tickers: EXEL, IMGN, ONXX, RHHBY

    Note: A Previous version of this post contained errors regarding Onyx's drugs kyprolis and Nexavar.

    ImmunoGen (NASDAQ: IMGN) went up significantly due to the recent FDA approval of Kadcyla as an additional therapy for breast cancer. Kadcyla is a novel drug using the antibody drug conjugate mechanism and developed under Targeted Antibody Payload (TAP) technology to kill cancer cells. The product was developed in collaboration with Genentech, a subsidiary more »

  • A Trio of Cancer Immunotherapy Innovators

    By Seth Robey - June 14, 2013 | Tickers: BMY, CLDX, IMGN, RHHBY, SGEN

    The cancer world has been abuzz after an exciting ASCO conference.  Bristol-Myer's Squibb (NYSE: BMY) presented really promising updates for its PD-1 inhibitor nivolumab in late-stage melanoma, leading one Citigroup analyst to declare "the beginning of the end of cancer."  With Merck and Roche (NASDAQOTH: RHHBY) also boasting PD-1 inhibitors we can only hope someone has a magic bullet.  But is there space in this massive market for the more »

  • Page 1 of 3